Please ensure Javascript is enabled for purposes of website accessibility

Better Cannabis Stock: Cronos Group vs. Tilray

By Keith Speights - Aug 14, 2020 at 6:44AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Both of these Canadian pot stocks are losers so far in 2020, but one seems better positioned to return to the winners' column.

There hasn't been much good news for either Cronos Group (CRON 3.93%) or Tilray (TLRY) so far this year. Both companies hoped that the Canadian cannabis retail environment would improve in 2020, but then the COVID-19 pandemic hit. 

Tilray has been by far the bigger loser year to date, with its shares down nearly 60% -- more than twice the size of the decline in Cronos stock. Which of these Canadian cannabis stocks is the better pick looking ahead? Here's how Cronos and Tilray compare. 

Hands holding two cannabis leaves with a blue sky in the background.

Image source: Getty Images.

The case for Cronos Group

Arguably the biggest reason to consider buying Cronos Group stock is the company's relationship with tobacco giant Altria Group (MO 0.04%). Altria invested $1.8 billion in early 2019 to buy a 45% stake in Cronos. The deal gave Cronos a strong cash position that has enabled it to weather turbulent times better than many of its peers.

Thanks to the influx of cash from Altria, Cronos expanded into the U.S. hemp CBD market relatively quickly. It acquired Redwood Holdings' Lord Jones upscale hemp CBD brands last year. Although the COVID-19 pandemic has weighed on sales of these products, Lord Jones could be a key growth driver for Cronos over the long run.

Cronos had already moved into Latin America prior to the Altria deal. In 2018, the company formed a cannabis joint venture, Natuera, in Colombia. Natuera gives Cronos a foothold in the growing medical cannabis market in Latin America. The joint venture also completed test exports of hemp-derived CBD extract to the U.S. earlier this year. While no revenue is being made from these exports at this point, it could position Cronos well for the future. 

The company also recently began selling medical cannabis products in Israel. Although Israel's population of a little over 9 million people is less than one-fourth the size of Canada's population, the country has a high cannabis usage rate. There's also much less black market competition in Israel.

Cronos still makes most of its revenue in its home market of Canada. The company's main growth driver in this market is its cannabis derivatives products. Cronos launched its vape products earlier this year.

The case for Tilray

Unlike Cronos Group, Tilray doesn't have a major equity partner. This certainly presents some disadvantages for the company. But it has also forced Tilray to focus more heavily on a path to profitability. The company announced major staffing cuts earlier this year. It now expects to achieve positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) by the end of 2020.

The lack of a deep-pocketed partner hasn't kept Tilray from expanding internationally. Last year, the company acquired Manitoba Harvest, the world's largest hemp foods manufacturer. This business now contributes roughly 40% of Tilray's total revenue.

Tilray also ranks as a leader in European medical cannabis markets. It established a cannabis production facility in Portugal that serves as a distribution hub for Europe. 

Germany stands out as the most important European market that Tilray targets. With a population more than twice the size of Canada, Germany could become a bigger medical cannabis opportunity for the company in the coming years than its home market. 

But don't underestimate Tilray's prospects in Canada. Like Cronos, Tilray has launched cannabis derivatives products. In the second quarter, these products generated around 22% of Tilray's total adult-use recreational marijuana sales. As the cannabis derivatives market gains momentum and more retail cannabis stores open in Canada, Tilray should have significant growth opportunities. 

Better cannabis stock

My view is that Cronos Group is the better cannabis stock right now over Tilray. The decision comes down primarily to the two companies' financial positions. Although Tilray hopes to achieve adjusted EBITDA profitability by the end of this year, Cronos' cash position resulting from its relationship with Altria puts it on firmer footing.

While Cronos gets the nod over Tilray, I don't think either of these cannabis stocks is a great pick to buy right now. There are too many uncertainties for both companies. Investors looking for ways to make money from cannabis can find better alternatives than either Cronos Group or Tilray.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cronos Group Stock Quote
Cronos Group
CRON
$3.17 (3.93%) $0.12
Tilray Stock Quote
Tilray
TLRY
Altria Group, Inc. Stock Quote
Altria Group, Inc.
MO
$45.15 (0.04%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.